C-reactive protein is a prognostic parameter in patients with cervical cancer

Polterauer, Stephan; Grimm, Christoph; Tempfer, Clemens; Sliutz, Gerhard; Speiser, Paul; Reinthaller, Alexander; Hefler, Lukas

doi:10.1016/j.ygyno.2007.06.001

Cited by 74 publications

(77 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are in line with those of Polterauer and colleagues, who in a large cohort of cervical cancer, mainly representing the squamous cell carcinoma subtype, observed that higher serum CRP levels were significantly associated with advanced tumour stage (14). A similar correlation between CRP and FIGO stage was also detected by Hefler et al in a group of patients with epithelial ovarian cancer (13).…”

Section: Discussionsupporting

confidence: 93%

“…These comprise the most common and established markers such as squamous cell carcinoma antigen, tissue polypeptide antigen, CEA and CA 12-5 (27,28). In accordance with previous research, the present study confirmed the prognostic role of CEA and CA 12-5 in cervical adenocarcinoma (14,27). Additionally, experimental inflammatory markers such as interleukin 1, interleukin 6 and interferon γ were found to be linked with impaired prognosis in cervical cancer (29).…”

Section: Discussionsupporting

confidence: 91%

“…Serum CRP was independently associated with OS. Our data are in line with those of Polterauer and co-workers and support the role of serum CRP as independent prognostic parameter in cervical adenocarcinoma (14). The major advantage of CRP is that it is already a recognized marker of inflammation which is relatively cheap and easy to assay and is generally used in daily clinical routine in laboratories worldwide.…”

Section: Discussionsupporting

confidence: 90%

“…To date, the prognostic value of serum CRP has been assessed in different human malignancies (25,26). However, literature regarding the prognostic role of serum CRP in cervical cancer is scanty and mainly focused on squamous cell carcinoma, with no separate data existing for the subset of cervical adenocarcinoma (14,16). Thus, we aimed to investigate if serum CRP could potentially serve as an additional independent prognostic marker for this histological subtype.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, an increase in serum CRP has been reported to be associated with poor prognosis in oesophageal, liver, colon and lung cancer (9)(10)(11)(12). Elevated serum CRP levels have also been linked to impaired survival in patients with different gynaecological malignancies, including cervical, ovarian and endometrial cancer (13)(14)(15). However, only few studies reported on the prognostic role of CRP expression in cervical carcinoma (14,16), with no data investigating exclusively the histological subtype adenocarcinoma of the uterine cervix.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Bodner‐Adler

Kimberger

Schneidinger

et al. 2016

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with peak incidence in the 40-to 45-year age group (1). Adenocarcinoma of the uterine cervix is a rare histological subtype, representing up to 20% of cervical carcinoma. International Federation of Gynaecology and Obstetrics (FIGO) stage, histological grade, tumour size, lymphovascular space invasion and lymph node metastasis are major prognostic factors reported in literature (1-3). Nevertheless, additional information guiding the patient's management would be helpful. There is much interest in prognostic factors to permit more accurate patient stratification, that will improve clinical decision-making and may contribute to more rational treatment options. Current guidelines for cervical cancer recommend the same treatment regardless of histological subtype, although lower survival rates were reported for the adenocarcinoma subtype (4). Therefore increasing efforts should focus on prognosticators in adenocarcinoma of the uterine cervix.C-Reactive protein (CRP) is widely used in clinical routine as the most important acute-phase serum protein for monitoring infection. CRP has also been shown to be elevated in patients with a variety of cancer types and an association with prognosis was found. Several studies have shown that patients with cancer have a higher level of circulating CRP than healthy controls prior to clinical diagnosis (5-8). In addition, an increase in serum CRP has been reported to be associated with poor prognosis in oesophageal, liver, colon and lung cancer (9-12). Elevated serum CRP levels have also been linked to impaired survival in patients with different gynaecological malignancies, including cervical, ovarian and endometrial cancer (13-15). However, only few studies reported on the prognostic role of CRP expression in cervical carcinoma (14, 16), with no data investigating exclusively the histological subtype adenocarcinoma of the uterine cervix.The aim of the present study was to evaluate whether the pre-treatment serum CRP level might be used as a prognostic parameter in patients with adenocarcinoma of the uterine cervix and to investigate a possible correlation between the serum CRP level and various clinicopathological parameters. 4691

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Bodner‐Adler

Kimberger

Schneidinger

et al. 2016

View full text Add to dashboard Cite

show abstract

The association between C‐reactive protein (CRP) level and biochemical failure‐free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate

Hall

Nickleach

Master

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND: C-reactive protein (CRP) has been associated with outcomes in patients with metastatic adenocarcinoma of the prostate. Associations between prostate adenocarcinoma-specific endpoints and CRP in patients who are treated for localized disease remain unknown. METHODS: In total, 206 patients who received radiation therapy for adenocarcinoma of the prostate had at least 1 CRP measured in follow-up and were analyzed. The primary outcome was biochemical failure-free survival. In addition, associations were examined between CRP and prostate-specific antigen (PSA). RESULTS: On univariate analysis, higher CRP levels were associated significantly with shorter biochemical failure-free survival for patients who received radiation therapy after undergoing radical prostatectomy. For patients who were managed with definitive radiation therapy alone, higher CRP levels also were associated significantly with shorter biochemical failure-free survival on univariate and multivariable analyses (hazard ratio, 2.03; 95% confidence interval, 1.19-3.47; P 5.009). In addition, CRP levels were associated significantly with PSA after radical prostatectomy for patients who had Gleason scores 8 (P 5.037), for high-risk patients (P 5.008), and for those with pretreatment PSA levels >20 ng=mL (P 5.05). In patients who received definitive radiation therapy, CRP levels also were associated with PSA both for those with pretreatment PSA levels >20 ng=mL (P <.001), and for the intermediate-risk (P 5.029) and high-risk (P 5.009) subgroups. CONCLUSIONS: A higher CRP level was associated with shorter biochemical failure-free survival on univariate and multivariable analyses in patients who received definitive radiation therapy. CRP was also associated with PSA in exploratory subgroups. These findings warrant further exploration in a prospectively enrolled patient cohort.

show abstract

Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

2014

View full text Add to dashboard Cite

show abstract

C-reactive protein is a prognostic parameter in patients with cervical cancer

Cited by 74 publications

References 29 publications

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix

The association between C‐reactive protein (CRP) level and biochemical failure‐free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate

Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

Contact Info

Product

Resources

About